Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Purchases $26,800.00 in Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Bernd R. Seizinger bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The shares were acquired at an average price of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now directly owns 44,730 shares of the company’s stock, valued at $119,876.40. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Aprea Therapeutics Trading Up 27.1 %

Shares of APRE stock opened at $4.45 on Friday. The stock has a market capitalization of $24.16 million, a price-to-earnings ratio of -1.34 and a beta of 1.03. Aprea Therapeutics, Inc. has a 12-month low of $2.15 and a 12-month high of $8.85. The stock’s 50-day moving average price is $3.18 and its 200-day moving average price is $4.19.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. As a group, research analysts predict that Aprea Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research report on Monday, August 12th.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises about 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.